APA (7th ed.) Citation

Awada, G., Dirven, I., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kockx, M., & Neyns, B. (2024). Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF V600 /NRAS Q61 Wild-Type Melanoma (TraMel-WT). JCO Precision Oncology, 8, 1. https://doi.org/10.1200/PO.23.00493

Chicago Style (17th ed.) Citation

Awada, Gil, Iris Dirven, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Mark Kockx, and Bart Neyns. "Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF V600 /NRAS Q61 Wild-Type Melanoma (TraMel-WT)." JCO Precision Oncology 8 (2024): 1. https://doi.org/10.1200/PO.23.00493.

MLA (9th ed.) Citation

Awada, Gil, et al. "Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF V600 /NRAS Q61 Wild-Type Melanoma (TraMel-WT)." JCO Precision Oncology, vol. 8, 2024, p. 1, https://doi.org/10.1200/PO.23.00493.